The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is sponsoring a US-wide Phase 2 trial of the M-001 Universal Flu vaccine from Israel’s BiondVax.  A 9,630-person, EU-financed Phase 3 trial is already scheduled.

http://nocamels.com/2018/05/us-turn-to-israeli-flu-vaccine-maker-outbreak/